Monitor the combined company's progress in migraine prevention clinical programs (MT-001, MT-002) and any CVR-related monetization of InMed's legacy cannabinoid assets. The $490M cash position provides runway for development.
Drugs in focus
MT-001
● Neutral Named in this 8-K- Impact
- Phase
- Preclinical (IND-enabling)
- Time to market
- Unknown — still preclinical. If successful through Phases 1-3, a potential approval would be 5+ years away.
- Next catalyst
- None dated
What to watchMT-001 is too early for a binary trade, no human data exists yet and Phase 2a data is two+ years out. The real near-term story for INM is the reverse-merger close (expected by Dec 31, 2026) and whether the $290M PIPE fully funds through 2028 as promised. Post-merger the ticker changes, so current INM holders are effectively buying Mentari's preclinical pipeline at the merged entity's valuation. Watch for the IND/CTA filing mid-2026 as a first proof of life.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 11 $15.61entry
- T+1 · 5d ago +17.56%α +17.91% · $18.35
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
InMed Pharmaceuticals completed its reverse merger with Mentari Therapeutics on November 6, 2026, with Mentari as the accounting acquirer. Former InMed shareholders received contingent value rights (CVRs) for legacy assets, while Mentari shareholders and PIPE investors own approximately 99% of the combined company. The combined company, renamed Mentari Therapeutics, Inc., will focus on migraine prevention therapies.
Key Financial Metrics
Key Facts
- Merger closed on November 6, 2026; InMed changed name to Mentari Therapeutics, Inc.
- Former Mentari stockholders own ~99% of combined company; InMed stockholders ~1%
- Mentari raised $490M in pre-closing financing (First Pre-Closing $290M, Second $200M)
- Exchange ratio: 0.20065 shares of InMed common stock per Mentari share
- InMed legacy assets (INM-901, INM-089, INM-755) placed into CVR structure for shareholders
- Combined company focused on migraine prevention; Mentari management team leads
- Fiscal year changed from June 30 to December 31
- Board reconstituted with 5 members; Julianne Bruno appointed Chair
- 2026 Stock Incentive Plan approved with initial pool of 9,618,697 shares
- Company ceased to be a shell company as of the closing date
Financial Impact
Mentari raised $490M in pre-closing financing; combined company pro forma cash ~$478M as of June 30, 2026
Risk Factors
- CVR holders may never receive any proceeds from legacy asset monetization
- Combined company has no approved products and is pre-revenue
- Integration risks and potential for higher-than-expected transaction costs
- Dependence on Paragon Therapeutics for antibody discovery and manufacturing
- document contains text addressed to automated readers
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-455640 |
| Document: d539218d8k.htm | 0001193125-26-455640 |
| Document: d539218dex107.htm | 0001193125-26-455640 |
| 8-K Data (Synthetic) | 0001193125-26-455640 |
Track record
10 reports on MTRI
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $17.90 Now $19.87 −11.01% settles Dec 15
- Nov 16, 2026today 8-K Neutral 6/10 Entry $18.60 Now $19.87 +6.83% settles Dec 15
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $19.02 Now $19.87 +4.47% settles Dec 15
- Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $15.75 Now $19.87 +26.16% settles Dec 15
- Nov 12, 20264d ago SC 13D Neutral 5/10 Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $18.60 Now $19.87 +6.83% settles Dec 14
- Nov 10, 20266d ago 8-K Mixed 7/10 Viewing Entry $15.61 Now $19.87 +27.30% settles Dec 10
- Nov 9, 20267d ago Press Release Neutral 2/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers